Fleisher Lee A
University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Curr Opin Anaesthesiol. 2007 Dec;20(6):526-30. doi: 10.1097/ACO.0b013e3282f19339.
Perioperative beta-blockade has been advocated by multiple authors and recent guidelines as a strategy to reduce cardiac risk in noncardiac surgery. Knowledge about application of this treatment modality to the ambulatory surgery population is poor.
Although the initial trial in patients with a positive stress test undergoing major vascular surgery demonstrated significantly fewer perioperative cardiac events among those randomized to perioperative beta-blocker therapy, more recent studies in patients without documented coronary artery disease undergoing major noncardiac surgical procedures were unable to demonstrate efficacy. Guidelines from the American Heart Association/American College of Cardiology have been reported and advocated class I recommendations for perioperative beta-blockade only for patients previously taking beta-blockers and those patients with a positive stress test undergoing vascular surgery. There was insufficient evidence to make a recommendation in low-risk surgery.
Based upon the available evidence and guidelines, patients currently taking beta-blockers and undergoing ambulatory surgery should continue these agents and protocols employing this strategy should be beneficial. In patients who are not currently taking beta-blockers and in whom long-term therapy is not warranted, current evidence does not support instituting prophylactic therapy in the ambulatory surgery population.
多位作者及近期指南都提倡围手术期使用β受体阻滞剂,作为降低非心脏手术心脏风险的一种策略。但对于该治疗方式在门诊手术人群中的应用,了解甚少。
尽管最初一项针对接受大血管手术且应激试验阳性患者的试验表明,随机接受围手术期β受体阻滞剂治疗的患者围手术期心脏事件显著减少,但近期针对未确诊冠心病且接受非心脏大手术患者的研究未能证明其有效性。美国心脏协会/美国心脏病学会的指南已发布,并仅对既往服用β受体阻滞剂的患者以及应激试验阳性且接受血管手术的患者推荐围手术期使用β受体阻滞剂为I类推荐。对于低风险手术,尚无足够证据给出推荐。
基于现有证据和指南,目前正在服用β受体阻滞剂且即将接受门诊手术的患者应继续服用这些药物,采用该策略的方案应是有益的。对于目前未服用β受体阻滞剂且无需长期治疗的患者,现有证据不支持在门诊手术人群中开展预防性治疗。